mtor inhibition alleviates mitochondrial disease mouse model leigh syndrome
mitochondrial dysfunction contributes numerous health problems including neurological muscular degeneration cardiomyopathies cancer diabetes pathologies aging severe mitochondrial defects can result childhood disorders leigh syndrome effective therapies found rapamycin specific inhibitor mechanistic target rapamycin mtor signaling pathway robustly enhances survival attenuates disease progression mouse model leigh syndrome administration rapamycin mice deficient mitochondrial respiratory chain subunit ndufs4 [nadh dehydrogenase ubiquinone fe-s protein ] delays onset neurological symptoms reduces neuroinflammation prevents brain lesions although precise mechanism rescue remains determined rapamycin induces metabolic shift toward amino acid catabolism away glycolysis alleviating buildup glycolytic intermediates therapeutic strategy may prove relevant broad range mitochondrial diseases
